About this series
This article is the first in our eight-part series, “Regulatory Challenges for Chinese Biotech Expanding Trials to Europe.” Each article will cover a critical aspect of Europe’s regulatory landscape to help Chinese biotech sponsors expand smoothly and compliantly.
Introduction
The EU Clinical Trials Regulation (EU CTR 536/2014) and the Clinical Trials Information System (CTIS) have transformed how clinical trials are approved and managed across multiple countries in European Union (EU) and European Economic Area (EEA). For biotech and pharmaceutical companies, especially those with no previous experience with the EU/EEA region, understanding this framework is essential to ensure smooth and regulatory compliant clinical trial submissions.
1. What the EU CTR Does
Fully applicable since 31 January 2022, the EU CTR replaces the old Clinical Trial Directive with a single, harmonized process binding for all EU and EEA Member States.
Its goals are to:
- Simplify submissions through one centralized online system (CTIS)
- Improve transparency and consistency of clinical trials conduct across EU/EEA
- Strengthen participant safety and oversight
The unified approach enables sponsors to submit a single application in multiple countries for a centralized assessment reducing the risk of potential duplication of queries and delays in review.
2. How It Differs from China’s IND System
Unlike China’s Investigational New Drug (IND) process, the EU CTR combines centralized scientific assessment (Part I) with national ethics review (Part II).
This means sponsors must plan carefully for documentation, translation, and review timelines.
Although it requires more upfront coordination, the EU CTR ultimately offers greater consistency and predictability for multinational studies.
3. Key Steps for a Successful Submission
To navigate the EU CTR effectively:
- Plan early for both Part I and Part II assessments.
- Align core documents (Protocol, Investigator’s Brochure, IMPD) with EU CTR, European Medicines Agency (EMA) and ICH GCP standards.
- Understand CTIS workflows, permissions, timelines and communication channels.
- Partner with an experienced CRO that bridges China–Europe regulatory practices.
Strong preparation and expert support are crucial for first-time CTIS applicants.
4. Turning Compliance into Opportunity
While adapting to the EU CTR may seem complex, it also builds sponsors’ global regulatory strength and data credibility.
Companies that invest in understanding the EU process can accelerate approvals, enhance transparency, and gain long-term advantages in global development.
Conclusion
The EU CTR sets a new standard for harmonized clinical trial governance in Europe. For biotech innovators expanding internationally, mastering EU CTR and CTIS processes is not just about compliance, it’s a pathway to faster, higher-quality global research.
Previous Blog: Regulatory Challenges for Chinese Biotech Expanding Trials to Europe
Next Blog: Bridging Regulatory Systems: From China’s IND to Europe’s CTA